The HEP-COVID Trial: Therapeutic Anticoagulation in Non-Critically Ill COVID-19 Patients

Background:┬áPatients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated inflammatory markers such as D-dimer levels are at an increased risk from thrombosis. Early studies … Continue reading The HEP-COVID Trial: Therapeutic Anticoagulation in Non-Critically Ill COVID-19 Patients